ASH 2023 | Itacitinib for the prevention of immune effector cell therapy–associated CRS
Matthew Frigault
• 12 Dec 2023
In this video, Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, briefly discusses a Phase II study exploring the use of the JAK1 inhibitor itacitinib as a strategy to prevent immune effector cell (IEC) therapy-associated cytokine release syndrome (CRS; NCT04071366). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, Kite, Novartis, Covance
Research Funding: Kite, Novartis, Arcellx
